Automated immunohistochemical assay for estrogen receptor status in breast cancer using monoclonal antibody CC4-5 on the Ventana ES

American Journal of Clinical Pathology

Volumn 106, Issue 3, 1996, Pages 332-338

  Nichols, Guy E ^a   Frierson Jr , Henry F ^a   Boyd, James C ^a   Hanigan, Marie H ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Breast cancer; CC4 5; Estrogen receptor; Immunohistochemistry; Monoclonal antibody

Indexed keywords

ESTROGEN RECEPTOR; MONOCLONAL ANTIBODY;

ARTICLE; AUTOANALYSIS; BREAST CANCER; CANCER HORMONE THERAPY; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; PRIORITY JOURNAL; STROMA; TUMOR NECROSIS;

EID: 0029758473     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcp/106.3.332     Document Type: Article

References (39)

1. Nicholson RI, McClelland RA, Gee JMW. Steroid hormone receptors and their clinical significance in cancer. J Clin Pathol 1995;48:890-895.
2. Rayter A. Steroid receptors in breast cancer. Br J Surg 1991;78: 528-535.
3. Ravdin PM. A practical view of prognostic factors for staging, adjuvant treatment planning, and as baseline studies for possible future therapy. Hematol Oncol Clin North Am 1994;8:197-211.
4. McGuire WL. Steroid hormone receptors in breast cancer treatment strategy. Rec Prog Hormone Res 1980;36:135-156.
5. Howell A, Harland RNL, Bramwell VHC, et al. Steroid-hormone receptors and survival after first relapse in breast cancer. Lancet 1984;1:588-591.
6. Borner M, Bacchi M, Goldhirsch A, et al. First isolated locoregional recurrence following mastectomy for breast cancer: Results of a phase III multicenter study comparing systemic treatment with observation after excision and radiation. Swiss Group for Clinical Cancer Research. J Clin Oncol 1994;12:2071-2077.
7. Wong K, Henderson IC. Management of metastatic breast cancer. World J Surg 1994;18:98-111.
8. Aamdal S, Bormer O, Jorgensen O, et al. Estrogen receptors and long-term prognosis in breast cancer. Cancer 1984;53:2525-2529.
9. de Mascarel I, Soubeyran I, MacGrogan G, et al. Immunohistochemical analysis of estrogen receptors in 938 breast carcinomas. Appl Immunohistochem 1995;3:222-231.
10. Battifora H, Mehta P, Ahn C, et al. Estrogen receptor immunohistochemical assay in paraffin-embedded tissue: A better gold standard? Appl Immunohistochem 1993;1:39-45.
11. Kell D, Kamel O, Rouse R. Immunohistochemical analysis of breast carcinoma estrogen and progesterone receptors in paraffin-embedded tissue: Correlation of clones ERID5 and 1A6 with a cytosol-based hormone receptor assay. Appl Immunohistochem 1993;1:275-281.
12. Hendricks J, Wilkinson E. Comparison of two antibodies for evaluation of estrogen receptors in paraffin-embedded tumors. Mod Pathol 1993;6:765-770.
13. Esteban JM, Ahn C, Battifora H, et al. Predictive value of estrogen receptors evaluated by quantitative immunohistochemical analysis in breast cancer. Am J Clin Pathol 1994;102:S9-S12.
14. Battifora H. Immunocytochemistry of hormone receptors in routinely processed tissues: The new gold standard. Appl Immunohistochem 1994;2:143-145.
15. Lee K, Chan J. 1D5: A superior anti-estrogen receptor antibody reactive in routine paraffin sections. Adv Anat Pathol 1994;1: 52-55.
16. Frierson H Jr., Wolber RA, Berean KW, et al. Interobserver reproducibility of the Nottingham modification of the Bloom and Richardson histologic grading scheme for infiltrating ductal carcinoma. Am J Clin Pathol 1995;103:195-198.
17. Hendersen C. Aminoallylsilane: An inexpensive, simple preparation for slide adhesion. J Histotechnol 1989;12:123-124.
18. Hanna W, McReady DR, Chapman JW, et al. The predictive value of ERICA in breast cancer recurrence: A univariate and multivariate analysis. Mod Pathol 1993;6:748-754.
19. McCarty K Jr., Miller L, Cox E, et al. Estrogen receptor analyses: Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 1985;109:716-721.
20. Aasmundstad TA, Haugen OA, Johannesen E, et al. Oestrogen receptor analysis: Correlation between enzyme immunoassay and immunohistochemical methods. J Clin Pathol 1992;45:125-129.
21. Maass H, Jonat W, Stolzenbach G, et al. The problem of nonresponding estrogen receptor-positive patients with advanced breast cancer. Cancer 1980;46:2835-2837.
22. Allred DD. Should immunohistochemical examination replace biochemical hormone receptor assays in breast cancer? Am J Clin Pathol 1993;99:1-2.
23. Pari FF, Posey YF. Discrepancies of the biochemical and immunohistochemical estrogen receptor assays in breast cancer. Hum Pathol 1988;19:960-966.
24. Ballouk F, Boguniewicz A, Ross JS, et al. Image analysis quantification in hormone receptor assay of mucinous carcinoma of the breast. Analyt Quant Cytol Histol 1995;17:151-156.
25. Pertschuk L, Kim D, Nayer K, et al. Immunocytochemical estrogen and progestin receptor assays in breast cancer with monoclonal antibodies: Histopathologic, demographic, and biochemical correlations and relationship to endocrine response and survival. Cancer 1990;66:1663-1670.
26. Kinsel L, Szabo E, Greene J, et al. Immunocytochemical analysis of estrogen receptors as a predictor of prognosis in breast cancer patients: Comparison with quantitative biochemical methods. Cancer Res 1989;49:1052-1056.
27. Glatstein IZ, Yeh J. Ontogeny of the estrogen receptor in the human fetal uterus. J Clin Endorinol Melab 1995;80:958-964.
28. Mizutani T, Nishikawa Y, Adachi H, et al. Identification of estrogen receptor in human adipose tissue and adipocytes. J Clin Endocrinol Melab 1994;78:950-954.
29. Abbondanza C, de Falco A, Nigro V, et al. Characterization and epitope mapping of a new panel of monoclonal antibodies to estradiol receptor. Steroids 1993;58:4-12.
30. Bier B, Bankfalvi A, Grote L, et al. Wet autoclave pretreatment for immunohistochemical demonstration of oestrogen receptors in routinely processed breast carcinoma tissue. Histochem J 1995;27:148-154.
31. McGuire WL, Chamness GC, Fuqua SA. Estrogen receptor variants in clinical breast cancer. Mol Endocrinol 1991;5:1571-1577.
32. Fuqua SA, Allred DC, Auchus RJ. Expression of estrogen receptor variants. J Cell Biochem Supplement 1993;17G:194-197.
33. Jiang SY, Langan-Fahey SM, Stella AL, et al. Point mutation of estrogen receptor (ER) in the ligand-binding domain changes the pharmacology of antiestrogens in ER-negative breast cancer cells stably expressing complementary DNAs for ER. Mol Endocrinol 1992;6:2167-2174.
34. Allegra J, Lippman M, Green L, et al. Estrogen receptor values in patients with benign breast disease. Cancer 1979;44:228-231.
35. Giani C, D'Amore E, Delarue J, et al. Estrogen and progesterone receptors in benign breast tumors and lesions: Relationship with histological and cytological features. Int J Cancer 1986;37:7-10.
36. Bezwoda WR, Esser JD, Dansey R, et al. The value of estrogen and progesterone receptor determinations in advanced breast cancer. Estrogen receptor level but not progesterone receptor level correlates with response to tamoxifen. Cancer 1991;68: 867-872.
37. Shek LL, Godolphin W. Survival with breast cancer: The importance of estrogen receptor quantity. Eur J Can Clin Oncol 1989;25:243-250.
38. Esteban JM, Kandalaft PL, Mehta P, et al. Improvement of the quantification of estrogen and progesterone receptors in paraffin-embedded tumors by image analysis. Am J Clin Pathol 1993;99:32-38.
39. Barnes DM, Millis RR, Fentiman IS, et al. Who needs steroid receptor assays? Lancet 1989;i:1126-1127.